These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 24827068)

  • 1. Relative importance of benefits and risks associated with antithrombotic therapies for acute coronary syndrome: patient and physician perspectives.
    Yuan Z; Levitan B; Burton P; Poulos C; Brett Hauber A; Berlin JA
    Curr Med Res Opin; 2014 Sep; 30(9):1733-41. PubMed ID: 24827068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial.
    Patel MR; Becker RC; Wojdyla DM; Emanuelsson H; Hiatt WR; Horrow J; Husted S; Mahaffey KW; Steg PG; Storey RF; Wallentin L; James SK
    Eur J Prev Cardiol; 2015 Jun; 22(6):734-42. PubMed ID: 24830710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antithrombotic strategies and outcomes in acute coronary syndrome with atrial fibrillation.
    Chamberlain AM; Gersh BJ; Mills RM; Klaskala W; Alonso A; Weston SA; Roger VL
    Am J Cardiol; 2015 Apr; 115(8):1042-8. PubMed ID: 25726381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial infarction.
    Schjerning Olsen AM; Gislason GH; McGettigan P; Fosbøl E; Sørensen R; Hansen ML; Køber L; Torp-Pedersen C; Lamberts M
    JAMA; 2015 Feb; 313(8):805-14. PubMed ID: 25710657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients.
    Chin CT; Boden WE; Roe MT; Neely B; Neely ML; Leiva-Pons JL; Corbalán R; Gottlieb S; Dalby AJ; Armstrong PW; Prabhakaran D; Fox KA; White HD; Ohman EM; Winters KJ; Schiele F
    Heart; 2016 Aug; 102(15):1221-9. PubMed ID: 27030601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes.
    Ducrocq G; Schulte PJ; Budaj A; Cornel JH; Held C; Himmelmann A; Husted S; Storey RF; Cannon CP; Becker RC; James SK; Katus HA; Lopes RD; Sorbets E; Wallentin L; Steg PG
    Am Heart J; 2017 Apr; 186():91-99. PubMed ID: 28454837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease.
    Lopes RD; Rao M; Simon DN; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Go AS; Hylek EM; Kowey P; Piccini JP; Singer DE; Chang P; Peterson ED; Mahaffey KW
    Am J Med; 2016 Jun; 129(6):592-599.e1. PubMed ID: 26797080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term versus short-term dual antiplatelet therapy was similarly associated with a lower risk of death, stroke, or infarction in patients with acute coronary syndrome regardless of underlying kidney disease.
    Carrero JJ; Varenhorst C; Jensevik K; Szummer K; Lagerqvist B; Evans M; Spaak J; Held C; James S; Jernberg T
    Kidney Int; 2017 Jan; 91(1):216-226. PubMed ID: 27865441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
    Aradi D; Komócsi A; Vorobcsuk A; Serebruany VL
    Thromb Haemost; 2013 Jan; 109(1):93-101. PubMed ID: 23197191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological therapy following acute coronary syndromes in patients with atrial fibrillation: how do we balance ischaemic risk with bleeding risk?
    Fake AL; Harding SA; Matsis PP; Larsen PD
    N Z Med J; 2016 May; 129(1435):39-49. PubMed ID: 27355167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention.
    Lamberts M; Gislason GH; Olesen JB; Kristensen SL; Schjerning Olsen AM; Mikkelsen A; Christensen CB; Lip GY; Køber L; Torp-Pedersen C; Hansen ML
    J Am Coll Cardiol; 2013 Sep; 62(11):981-9. PubMed ID: 23747760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit.
    Rothberg MB; Celestin C; Fiore LD; Lawler E; Cook JR
    Ann Intern Med; 2005 Aug; 143(4):241-50. PubMed ID: 16103468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome.
    Hess CN; Clare RM; Neely ML; Tricoci P; Mahaffey KW; James SK; Alexander JH; Held C; Lopes RD; Fox KAA; White HD; Wallentin L; Armstrong PW; Harrington RA; Ohman EM; Roe MT
    Am Heart J; 2017 May; 187():194-203. PubMed ID: 28454804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A risk score to predict bleeding in patients with acute coronary syndromes.
    Mehran R; Pocock SJ; Nikolsky E; Clayton T; Dangas GD; Kirtane AJ; Parise H; Fahy M; Manoukian SV; Feit F; Ohman ME; Witzenbichler B; Guagliumi G; Lansky AJ; Stone GW
    J Am Coll Cardiol; 2010 Jun; 55(23):2556-66. PubMed ID: 20513595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world observations with prasugrel compared to clopidogrel in acute coronary syndrome patients treated with percutaneous coronary intervention in the United States.
    Bae JP; Faries DE; Ernst FR; Lipkin C; Zhao Z; Moretz C; Lieu HD; Effron MB
    Curr Med Res Opin; 2014 Nov; 30(11):2207-16. PubMed ID: 25034466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of chronic kidney disease on long-term ischemic and bleeding outcomes in medically managed patients with acute coronary syndromes: Insights from the TRILOGY ACS Trial.
    Melloni C; Cornel JH; Hafley G; Neely ML; Clemmensen P; Zamoryakhin D; Prabhakaran D; White HD; Fox KA; Ohman EM; Armstrong PW; Roe MT
    Eur Heart J Acute Cardiovasc Care; 2016 Oct; 5(6):443-454. PubMed ID: 26228448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel.
    Wilcox R; Iqbal K; Costigan T; Lopez-Sendon J; Ramos Y; Widimsky P
    Curr Med Res Opin; 2014 Nov; 30(11):2193-205. PubMed ID: 25025610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiplatelet intervention in acute coronary syndrome.
    Arora RR; Rai F
    Am J Ther; 2009; 16(5):e29-40. PubMed ID: 19092648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Values and preferences for oral antithrombotic therapy in patients with atrial fibrillation: physician and patient perspectives.
    Alonso-Coello P; Montori VM; Díaz MG; Devereaux PJ; Mas G; Diez AI; Solà I; Roura M; Souto JC; Oliver S; Ruiz R; Coll-Vinent B; Gich I; Schünemann HJ; Guyatt G
    Health Expect; 2015 Dec; 18(6):2318-27. PubMed ID: 24813058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of stroke/transient ischemic attack among patients with acute coronary syndromes in a real-world setting.
    Deitelzweig SB; Ogbonnaya A; Berenson K; Lamerato LE; Costas JP; Makenbaeva D; Corbelli J
    Hosp Pract (1995); 2010 Nov; 38(4):7-17. PubMed ID: 21068522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.